Breast Cancer Core Needle Biopsy (CNB) Market Size

Breast Cancer Core Needle Biopsy Market Size

Breast Cancer Core Needle Biopsy Market size was valued at USD 776.5 million in 2023 and is estimated to grow at a CAGR of 7.8% from 2024 to 2032. The market has experienced substantial growth due to the rising incidence of breast cancer, which has significantly increased the demand for early diagnosis.

To get key market trends

  Download Free Sample

For instance, according to the World Health Organization (WHO), approximately 2.3 million women were diagnosed with breast cancer globally in 2022. This trend has led to a higher adoption of various biopsy techniques, including CNB, thereby fuelling market growth. Additionally, growing awareness among women about the importance of early breast cancer diagnosis has surged the demand for cancer screening programs. As more women participate in these programs, there is an increased need for minimally invasive diagnostic procedures like CNB.

This rising demand for cancer screening and diagnostic facilities has been a significant driver of market growth for breast cancer core needle biopsy. Furthermore, advancements in imaging technology and breast biopsy devices are improving the accuracy and safety of CNB, further driving its adoption in both developed and emerging markets.

CNB refers to a minimally invasive diagnostic procedure used to extract a small core of tissue from a suspicious area in the breast for pathological examination. This procedure is critical for diagnosing breast cancer, providing detailed tissue architecture that helps determine the presence and type of cancer cells. CNB is typically guided by imaging technologies.